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Abstract
Background: Human papillomaviruses (HPVs) are the primary etiological agents of cervical cancer and are also involved in
the development of other tumours (skin, head and neck). Serological survey of the HPV infections is important to better
elucidate their natural history and to disclose antigen determinants useful for vaccine development. At present, the analysis of
the HPV-specific antibodies has not diagnostic value for the viral infections, and new approaches are needed to correlate the
antibody response to the disease outcome. The aim of this study is to develop a novel ELISA, based on five denatured
recombinant HPV16 proteins, to be used for detection HPV-specific antibodies.
Methods: The HPV16 L1, L2, E4, E6 and E7 genes were cloned in a prokaryotic expression vector and expressed as histidine-
tagged proteins. These proteins, in a denatured form, were used in ELISA as coating antigens. Human sera were collected from
women with abnormal PAP smear enrolled during an ongoing multicenter HPV-PathogenISS study in Italy, assessing the HPV-
related pathogenetic mechanisms of progression of cervical cancer precursor lesions. Negative human sera were collected
from patients affected by other infectious agents. All the HPV-positive sera were also subjected to an avidity test to assess the
binding strength in the antigen-antibody complexes.
Results: Most of the sera showed a positive reactivity to the denatured HPV16 proteins: 82% of the sera from HPV16 infected
women and 89% of the sera from women infected by other HPV genotypes recognised at least one of the HPV16 proteins.
The percentages of samples showing reactivity to L1, L2 and E7 were similar, but only a few serum samples reacted to E6 and
E4. Most sera bound the antigens with medium and high avidity index, suggesting specific antigen-antibody reactions.
Conclusion: This novel ELISA, based on multiple denatured HPV16 antigens, is able to detect antibodies in women infected
by HPV16 and it is not genotype-specific, as it detects antibodies also in women infected by other genital HPVs. The assay is
easy to perform and has low cost, making it suitable for monitoring the natural history of HPV infections as well as for detecting
pre-existing HPV antibodies in women who receive VLP-based HPV vaccination.
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Background
Human Papillomaviruses (HPVs) infect cutaneous, geni-
tal, and respiratory epithelia in tissue-specific manner.
Papillomaviruses are non-enveloped viruses with a dou-
ble-strand DNA genome of 8 Kb. The genome is encapsi-
dated in an icosahedral structure of 55 nm-diameter,
composed of the L1 and L2 proteins, which are the major
and minor capsid protein, respectively. The HPV16
genome codes for several non-structural proteins: E1, E2,
E4, E5, E6 and E7. E1 and E2 are essential in viral tran-
scription and replication, E4 binds cytokeratins and is
involved in modification of the cytoskeleton network; E5
affects cellular receptors of growth factors, whereas E6 and
E7 are the major transforming proteins [1].
HPV infections are widespread in the general population,
and viral infection is closely associated to both benign
and malignant lesions [2,3]. Studies performed by several
groups have recently established that only few of the over
30 genital HPV genotypes described, are important risk
factors for developing high-grade of cervical intraepithe-
lial neoplasia (CIN3) and cervical cancer (CC), with a
high prevalence of genotype 16 [4,5]. Serological studies
are important to understand the natural history of HPV
infections, and during the past 15 years, efforts have been
made to develop reliable genotype-specific serological
assays. Most of the sero-epidemiological studies have
focused on confirming the relationship between the pres-
ence of HPV antibodies and the detection of anogenital
cancers or their precursors. The majority of these studies
have used either virus like particles (VLPs) or E6/E7 onco-
protein-based serological assays, while other HPV pro-
teins have been used as antigens less frequently [2,6,7].
The main conclusion from these sero-epidemiological
studies is that the antibody response to HPV16 proteins
does not invariably occur during a natural HPV infection.
For example a humoral immune response to VLPs is
induced in about half of the women with normal cytology
and HPV DNA presence in their cervical epithelium. The
VLP-specific antibodies are neutralizing and genotype-
specific and have been crucial for the development of pre-
ventive HPV vaccines [8,9]. An anti-HPV16 E6/E7
response has been predominantly found in patients with
advanced CC, but it has also been found in control
patients, making doubtful the use of serology in cancer
prediction [10]. However prospective cohort studies using
a widespread panel of viral antigens are urgently needed
to improve our understanding on HPV seroconversion in
patients with and without cervical lesions, as well as to
study the dynamics of antigen-specific HPV antibodies in
relation to the clinical outcome of the viral infection.
This paper reports the development of an in-house ELISA
system, based on five HPV16 proteins expressed in
Escherichia coli (E. coli). The assay uses the recombinant
viral L1 and L2 capsid proteins, E6 and E7 oncoproteins,
and non-structural E4 protein, all in denatured form. The
assay has been tested to monitor the antibody response in
women enrolled in the HPV-PathogenISS cohort to study
the HPV-related pathogenetic mechanisms of CIN pro-
gression in HIV-negative and HIV-positive women [11].
Results and discussion
Analysis of the HPV genotypes
Before testing the 99 sera for the presence of HPV antibod-
ies, DNA samples from cervical smears of the same
patients were analysed for the presence of HPV DNA, fol-
lowed by virus genotyping. HPV sequences were found in
all the samples, but the identification of a specific HPV
genotype was possible only in 66 samples. In the present
study these 66 cases were considered (Table 2). Among
the 18 genotypes detected, 12 (66.7%) were "high risk"
HPV (HR-HPV), 1 (genotype 90) was of "indeterminate
risk" and 5 were "low risk" HPV (LR-HPV) according to
the epidemiological classification of Munoz and co-work-
ers [12]. The most common HPV genotypes in descending
order of frequency were: HPV16 (33.3%), HPV35 (9.1%),
HPV31 (7.5%), HPV6-18-52-66 (6%). HPV16 was the
most prevalent genotype; half of the infections were asso-
ciated to the HR 16, 35, 31 genotypes, whereas HPV18
was found in only 6% of the women. The prevalence of
HPV16 is similar to that previously reported in Italy [13-
17] whereas that of the other genotypes is very different,
probably due to the small number of samples analysed.
Analysis of specific antibodies in HPV patients
To study the HPV-specific antibody response, several ELI-
SAs were set up in parallel using the recombinant HPV16
L1, L2, E4, E6 and E7 proteins as coating antigens. Figure
1 shows the SDS-PAGE analysis of the proteins expressed
in E. coli and purified. The protein pattern shows bands of
expected molecular mass; the level of protein purity is
over 95%. The proteins were inoculated into mice to gen-
erate specific hyper-immune sera. All the viral proteins
showed high immunogenicity, inducing specific antibod-
ies reacting with the corresponding antigen in ELISA,
Immunoprecipitation and in Western blotting experi-
ments (data not shown).
In the attempt to identify HPV specific and pan-reactive
antibodies, we set up an ELISA using the HPV16 recom-
binant proteins in denatured form, with carefully deter-
mined cut-off values (see below). Among the 66 sera
examined, 22 derived from women infected by HPV16,
while 44 cases from women infected by other HPV geno-
types. The results of a representative multiple HPV-ELISA
are shown in Figure 2. The results of seroreactivity to the
single HPV16 proteins, related to the HPV genotype data,
are listed in Table 2. The highest number of positive reac-Infectious Agents and Cancer 2006, 1:6 http://www.infectagentscancer.com/content/1/1/6
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tivity was observed against L1, L2 and E7, while only a few
sera had antibodies to E6 and E4. Only few sera were able
to react with all the HPV16 antigens and were collected
from women infected by HPV16, 31, 35, 6, 6b, 11 and 90
genotypes. These genotypes are correlated to some extent
[18]; HPV31 and 35 belong to the same viral species as
HPV16; HPV6, 6b and 11 belong to species related to
HPV16, whereas HPV90 belongs to a species only dis-
tantly related to HPV16. The reactivity to E6 was always
associated with reactivity to other viral antigens as well.
Some sera reacted only to one antigen, which was L1, L2,
E4 or E7. Among the 22 sera from HPV16-positive
women, 18 (82%) were positive at least to 1 HPV16 pro-
tein, while the rest (18%) were negative to all proteins.
The negative result indicates a complete lack of antibody
response in the patient, although we cannot exclude that
the presence of mutations in the genome of infecting virus
could determine the lack of antibody reactivity.
Among the 44 sera of women infected by other HPV gen-
otypes, 39 (89%) reacted at least to one of the five HPV16
proteins, and only 5 (11%) did not react at all. Of all the
66 sera analysed, 57 (86%) were reactive at least to one
HPV16 protein, and 9 sera (14%) were entirely negative.
The reproducibility of the assay was high as indicated by
the inter-assay Coefficient of Variation (CV) of about 5%.
The response of the different sera to the same antigen is
variable and the differences might reflect the different
stage of viral infections.
Figure 3 shows the percentage of sera positive to each pro-
tein in the two groups of sera: 1) HPV16 and 2) other
HPVs. In the first group, the percentage of sera reactive to
L2 (64%) is higher than that reactive to L1 (50%) or E7
(50%). In the second group the percentage of sera reacting
to E7 (68%) is higher than that reactive to L2 (52%) or
L1(45%). Of note the percentage of sera reacting to E7 is
higher in the group infected by other HPVs rather than in
the HPV16 group. These data suggest that linear and
immunogenic epitopes are present in these proteins; these
linear epitopes are shared by several genotypes, and
account for the cross-reactivity among the sera of women
infected by different HPV genotypes.
The percentage of negative sera, shown in Figure 3, is 18%
and 11% respectively in the HPV16 and in the other HPVs
group. This finding could suggest that HPV16 is less
immunogenic than the other HPV genotypes, at least as
far as it concerns the humoral response against linear
epitopes revealed by our immunoassay. A different immu-
nogenicity of HPV genotypes could account for the mark-
edly different prevalence of HPV genotypes in different
geographic regions [5]. Taken together, these results sug-
gest that our multiple ELISA system, based on denatured
HPV16 proteins, could be used for detection of HPV-spe-
cific antibodies in women infected by different viral gen-
otypes, although a larger number of sera needs to be
analysed for its standardization.
Avidity of the HPV antibodies
The Avidity Index (AI) of specific immunoglobulins is a
useful parameter for diagnosis of primary or past infection
in a large number of viral diseases [19]. It is well known
that after an infection or an immunization, the titer of
serum specific immunoglobulin as well as the antibody
affinity to the antigen, increase [20]. Several studies have
shown that early after an infection serum antibodies have
an AI lower than 40%; during the infection the AI values
progressively increase with time after infection, achieving
an AI higher than 60% [21-24]. This parameter is meas-
ured by assaying the resistance of antigen-antibodies com-
plexes to denaturing substances [25]. To evaluate the
specificity of each antigen-antibody complex in this HPV-
ELISA, we determined the AI in 32 sera positive to L1, 36
to L2, 19 to E4, 22 to E6 and 41 to E7. The HPV-specific
mouse hyper-immune sera and the commercial mono-
clonal antibodies described in Methods were used as a
control of the assay. The AI values of the hyper-immune
sera were: 44% (anti-L1), 50% (anti-L2), 78% (anti-E4),
26% (anti-E6) 46% (anti-E7). The anti-L1 and anti-E7
mAb AIs were 3% and 5% respectively; the anti-His mAb
AI was 20%. The AI results of the human sera are summa-
Table 1: HPV primers used in PCR amplification of the HPV 16 genes.
Primer DNA sequence Gene target Nucleotide positions in NCBI no NC_001526
L1_Sfor 5-GCCGTCGACATGTCTCTTTGGCTGCCTAGTAGGGCCA-3' Late protein L1 5637–5663
L1_Srev 5'- GCCGTCGACGATTTGTAGTAAAAATTTGCGTCC-3' Late protein L1 7027–7050
L2_Bfor 5'-GCGCGGATCCATGcgacacaaacgttctgcaa -3' Late protein L2 4235–4256
L2_Hrev 5'-GCGCAAGCTTCTAGGCAGCCAAAGAGACATC -3' Late protein L2 5636–5656
E6_Bfor 5'-GCGCGGATCCATGCACCAAAAGAGAACTGC3' Early protein E6 83–102
E6_Hrev 5'-GCGCAAGCTTTTACAGCTGGGTTTCTCTACGTG -3' Early protein E6 537–559
E4_Bfor 5'-GCGCGGATCCATGTATTATGTCCTACATCTGTGTTT -3' Early protein E4 3332–3357
E4_Hrev 5'-GCGCAAGCTTCTATGGGTGTAGTGTTACTATTA-3' Early protein E4 3597–3619
The start and stop codons are bolded while the restriction sites (Sal I, Bam HI, and Hind III) are underlinedInfectious Agents and Cancer 2006, 1:6 http://www.infectagentscancer.com/content/1/1/6
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rised in Table 3. Most samples showed an AI higher than
40% against L1, L2, E7 and E4, but not E6. In the HPV16
group, 40 samples showed an AI higher than 40%, and
the AI was below 40% in only 7 samples. In the second
group (other HPVs), 85 samples showed an AI higher
than 40%, and 18 samples had AI lower than 40%. Most
serum samples positive to E6 showed a low AI. Summariz-
ing, four out of five HPV16 proteins tested as antigens
seem to be able to bind antibodies with high avidity (AI
>40%). These results suggest that L1, L2, E4 and E7 in
denatured form could be considered as valid antigens to
be used in immunoassays. This is not the case of the
HPV16 E6 protein, the linear epitopes of which are recog-
nised with weak avidity by the antibodies. The presence of
immunoglobulins with high avidity in the HPV sera
might suggest that most of the women with abnormal
PAP test enrolled in this cohort have been infected for a
prolonged time. This issue merits further investigation,
because comprehensive data on the appearance of HPV-
specific antibodies to each viral protein and on the varia-
tion of their avidity have not been reported before.
Conclusion
In this study, an in-house ELISA based on the recom-
binant HPV16 L1, L2, E4, E6 and E7 proteins in denatured
form has been developed and used for the parallel detec-
tion of specific antibodies in sera collected from women
with abnormal PAP smears. The results show that this
assay has an increased sensitivity compared to the tests
based only on one viral protein, resulting in detection of
a higher number of positive sera. The assay is not geno-
type-specific but it can be used to detect antibodies raised
against genital HPVs other than type 16. This suggests that
the 5 proteins belonging to different HPV genotypes share
linear epitopes, as could be deduced from the high level
of amino acid identity of these proteins. By comparing the
amino acid sequences of the HPV16 L1, L2, E4, E6 and E7
to those of the other genotypes found in our study, the
highest identity (>65%) is found among the L1 proteins.
The homology among the E7 proteins is over 50%, similar
to that of the E6 proteins, in contrast to L2, where homol-
ogy is less than 50%. The sequence identity among the E4
proteins of related genotypes is less than 40%, and even
less among distantly related genotypes (data not shown).
The specificity of the antigen-antibody interactions in the
ELISA was indirectly measured by the avidity test, where
immunoglobulins non-specifically bound to denatured
proteins were removed by the urea treatment. As dis-
cussed above, most of the HPV-specific antibodies bound
to the 5 antigens had AI higher than 40%, implicating spe-
cific antigen-antibody reactions, even in the sera of
women infected with HPV other than type 16. These
results suggest that the ELISA combined with the Avidity
Index might improve the diagnostic value of serology sur-
vey in HPV infections.
Table 2: HPV Genotypes and Serostatus.
Serum n° HPV Sero-reactivity to HPV16 Proteins
L1 L2 E4 E6 E7
1 1 6 PPPPP
21 6 P P
3 1 6 PPPPP
41 6 P
51 6
61 6 P P
7 1 6 PPPPP
81 6 P P P
91 6 P P P
10 16 P
11 16 P
12 16 P P P
13 16 P P
14 16
15 16 P
16 16 P
17 16 P
18 16 P
19 16 P P P
20 16
21 16 P P P P P
22 16
23 35 P
24 35 P P P P P
25 35
26 35 P
27 35 P
28 35 P P P
29 31
30 31 P
31 31 P P P
32 31 P P P P P
33 31 P
34 6 P
3 5 6PPPPP
36 6 P P
37 6 P P
38 52 P P P P
39 52 P
40 52 P
41 52 P P
42 18 P
43 18 P P P
44 18
45 18 P
46 66 P P
47 66 P P
48 66 P P P
49 66
50 53 P P P P
51 53 P
52 53 P P
53 51 P P P
54 51 P
55 56
56 56 P
57 81 P P P P
58 81 P P P P
59 6b P P P P P
60 11 P P P P P
61 39 P P
62 42 P P
63 54 P P
64 58 P P P P
65 73 P P P P
66 90 P P P P P
P, positive test; empty cells represent negative tests.Infectious Agents and Cancer 2006, 1:6 http://www.infectagentscancer.com/content/1/1/6
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Due to the limited number of sera tested in the present
study, it is evident that this ELISA system needs validation
in large-scale population studies, especially for the detec-
tion of HPV pan-reactive antibodies in people infected by
genotypes different from HPV16. Nevertheless, in view of
the known cross-reactivity between the most common
HPV genotypes circulating in Europe [5,25], this ELISA
should be useful in monitoring the pre-existing serostatus
of women who receive HPV vaccination with the recently
introduced prophylactic VLP-based vaccines.
In conclusion, the results of the ELISA introduced in this
study are encouraging even though further investigations
are needed to evaluate its usefulness in population screen-
ing for HPV infections. Moreover the assay is easy to set up
since the recombinant proteins expressed and purified
from E. coli are cost-effective and easy-to-standardize sero-
logical reagents [27-30]. The Histidine tail of these pro-
teins allows a one-step purification procedure [31] and
the purified proteins are readily applicable to novel plat-
form technologies, which are useful when high numbers
of samples need to be processed [32,33].
Methods
DNA constructs
The HPV16 genes were generated by PCR on pMHPV16d
plasmid containing the complete virus genome (Acces-
ELISA based on HPV16 L1, L2, E4, E6 and E7 coating antigens Figure 2
ELISA based on HPV16 L1, L2, E4, E6 and E7 coating 
antigens. Detection of specific immunoglobulins to the 
HPV16 proteins in sera of women infected by HPV 16 
(empty dots) or by other HPVs (black dots). The protein 
used as coating antigen is indicated on each panel. In abscissa 
is reported the number of each serum as listed in Tab.2; in 
ordinate is reported the optical density of each reaction.
Analysis of purified proteins by SDS-PAGE Figure 1
Analysis of purified proteins by SDS-PAGE. The puri-
fied HPV16 proteins E4, E6, E7, L1 and L2 were run on a 
polyacrilamide gel electrophoresis and stained by Coomassie 
blue. Each protein is indicated on the top of the correspond-
ing lane. The weight of the molecular mass markers (lane M) 
is indicated on the left of the figure.
M    E4  E6   E7   L1   L2
188
98
62
49
28
14
6
3Infectious Agents and Cancer 2006, 1:6 http://www.infectagentscancer.com/content/1/1/6
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sion number NCBI NC_001526) [34], kindly provided by
A. Venuti, using specific primers carrying restriction sites
useful for cloning in pQE-30 expression vector (QIA-
GEN), and were expressed as MRGS (H)6 tag proteins
(Table 1). Cloning and expression of E7 (297 nt) were
previously described by Accardi et al. 2005. A truncated
form of L1 gene (1416 nt), was cloned into the restriction
site SalI, the expressed protein starts at the second methio-
nine of the L1 coding region and stops before the nuclear
localization signal. The L2 (1422 nt), E6 (477 nt) and E4
(288 nt) genes were cloned between the restriction sites
BamHI-HindIII of the vector. The plasmids were main-
tained in E. coli JM109 strain. The authenticity of the con-
structs was confirmed by DNA sequencing. The deduced
amino acid sequences of the inserts were compared to
those of the HPV16 (NC_001526), showing 100% iden-
tity.
Protein expression, purification, SDS-PAGE, and Western-
blot analysis
The recombinant proteins were purified using a denatur-
ing protocol: bacterial cells transformed by L1, L2, E4, and
E7 plasmids were lysed in a Phosphate buffer (100 mM
Na2HPO4 300 mM NaCl, 10 mM Tris, 1% Triton X-100,
pH 8), containing 8 M urea, while bacterial cells trans-
formed by E6 plasmids were lysed in Phosphate buffer,
containing 6 M Guanidine-HCl. Proteins were purified by
affinity chromatography on Ni-NTA resin and eluted by a
pH gradient. The fractions containing the proteins were
pooled, adjusted to a neutral pH by adding Tris pH 8.8
and stored in urea buffer at -30°C, until use. Protein con-
centration was determined by standard method (BC pro-
tein assay, BIORAD). To evaluate the purity, each protein
samples of L1, L2, E4, E6 and E7 were denatured in SDS-
loading buffer (25 mM Tris-HCl pH 6.8, 5 % β-Mercapto-
ethanol, 2% SDS, 50% glycerol), separated in pre-cast gel
Nu-PAGE MES-SDS (INVITROGEN), stained by Gel Code
Blue Stain Reagent (PIERCE). The proteins were identified
by Western blot using the monoclonal anti poly-Histidine
antibody Clone HIS1 (Sigma-Aldrich). A peroxidase-con-
jugate goat anti-mouse IgG (H+L) (SBA-INC USA) was
used as secondary antibody. The immune-complexes were
revealed by chemiluminescence (Amersham Bioscience).
HPV genotype identification
HPV genotyping was performed by sequence analysis.
DNA was extracted from the cells of cervical smears by
QIAamp DNA mini kit (QIAGEN). To assess DNA integ-
rity, the beta-globin gene was PCR amplified in each sam-
ples by the primers PCO3 and PCO4 [35]. To determine
the presence of HPV DNA, each DNA sample was sub-
jected to PCR amplification by the consensus primers
GP5+/GP6+, which amplify a L1 region [36]. When the
PCR result was negative and the serological test was posi-
tive, the DNA samples were further subjected to a semi-
nested PCR using the MY11-GP6+ primers in the first
round [37,38], and the GP5+/GP6+ couple of primers in
the second round. Amplicons were detected by agarose gel
electrophoresis, eluted by GFX PCR-DNA gel-band purifi-
cation kit (Amersham Bioscience) and sequenced using
the consensus primers GP5+/GP6+. The nucleotide
sequences were aligned to the Gene-Bank Database
sequences, using the BLAST program of the National
Center for Biotechnology Information (NCBI) server [39].
A sequence identity of 98% was considered significant for
the identification of the HPV genotype. The genotypes
identified in the samples were HPV 6, 11, 16, 18, 31, 35,
39, 42, 51, 52, 53, 54, 56, 58, 66, 73, 81 and 90.
Comparison of the percentages of sero-reactivity Figure 3
Comparison of the percentages of sero-reactivity. 
The percentages of sera reacting to the HPV16 L1, L2, E4, E6 
and E7 proteins are shown; the percentages of the HPV16 
serum group are in white bars and those the other HPVs 
serum group are in black bars. The percentages of negative 
sera in the two groups (Neg) are also given.
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11% 68% 32% 27% 52% 45%
18% 50% 23% 18% 64% 50% HPV16
Other HPVs
HPV16
Other HPVs 
Table 3: Avidity Index in the two serum groups.
HPV16 Group: L1 L2 E4 E6 E7 Tot
High AI > 40 10 14 6 10 40
Low AI < 40 1 5 1 7
Other HPVs Group:
High AI > 40 21 22 11 3 28 85
L o w  A I  <  4 0 21 42 1 8Infectious Agents and Cancer 2006, 1:6 http://www.infectagentscancer.com/content/1/1/6
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Human sera and control sera
The sera analysed in this study were collected from
women enrolled in the HPV-PathogenISS study. The
women had an abnormal PAP smear as requested for the
study design [11]. Only 99 women, of the 244 enrolled,
gave the informed consent for serum taking. Serum sam-
ples were kept at -30°C, until used for analyses. Negative
sera were randomly chosen among sera of individuals
infected by other pathogens. As positive controls specific
hyperimmune sera were used, obtained either in mice or
in rabbits by injection of the recombinant purified HPV16
L1, L2, E4, E6 and E7 proteins. The use of hyperimmune
anti-E7 polyclonal antibody has been reported before [40-
42]. The immunisation protocol was as previously
described in Di Bonito et al. [28].
ELISA and avidity test
The denatured HPV16 recombinant proteins (0.25 μg/
well) were adsorbed in carbonate buffer (pH 9.4) into
Polysorp microtiter plates (NUNC) at 4° O/N. After a
blocking step of 2 h at 37°C in phosphate buffer saline
(PBS) containing 3% Non Fat Dry Milk (NFDM), the
plates were incubated with 100 μl of human sera diluted
1:50 in 1% NFDM-PBS, at 37°C for 1 hr. The specific anti-
gen-antibody complexes were detected by a peroxidase-
conjugated goat anti-human IgG (H+L) (SBA INC. USA),
using the TMB (VECTOR) as a substrate. After 30 min, the
enzymatic reaction was stopped by adding 50 μl of 1 M
sulphuric acid/well. Optical density was read at 450 nm.
Washing steps were done with 200 μl/well of PBS contain-
ing 0.05 % Tween 20. The Monoclonal anti-poly-Histi-
dine antibody was used as control of the coating step.
The avidity test was performed as described by Roque-
Afonso et al. [25]. Serum samples were processed in par-
allel by a traditional ELISA and by an ELISA enclosing a 6
M urea-wash step. After incubation of serum samples with
the antigens, the wells were washed three times (5 min
each) with a PBS wash-buffer containing or not 6 M urea.
Each reaction was done in duplicate. A final fourth PBS-
wash was done in all wells. The Avidity Index (AI) was cal-
culated as follows: AI = (absorbance reading with urea
wash/absorbance reading without urea wash) × 100. The
HPV- specific hyperimmune sera to L1, L2, E6, E7 and E4,
the commercial anti-Histidine mAb (clone HIS-1, Sigma-
Aldrich), anti- HPV16 L1 mAb (clone CamVir-1, Cymbus
Biotechnology) and the anti-HPV16E7 mAb (clone 8C9,
Zymed Laboratories INC) were used as controls.
Cut-off definition and statistical analysis
To determine the cut-off values for each antigen, 40 con-
trol human sera were tested in ELISA against each of the
five HPV recombinant proteins. The assay included the
endpoint titre of the corresponding hyper-immune HPV
sera as a positive control. The cut-off value was calculated
as the arithmetic mean of the absorbance values of the
negative sera, plus two standard deviation (SD). After the
first cut-off calculation, the values of outlier serum sam-
ples were excluded, and the cut-off was re-calculated
[43,44]. To control the reproducibility of the test, ten rep-
resentative control human sera, the anti-poly-Histidine
mAB and the hyperimmune serum specific to each HPV
protein were always enclosed in each ELISA run. Each
serum was assayed in duplicate and the mean of the
absorbance value was taken as the final readout; the ELISA
for each HPV protein was repeated three times. To evalu-
ate the human serum variability, Coefficient of Variation
(CV = SD/Mean × 100) was calculated [45]. All statistical
tests were performed by Microsoft Office Excel software.
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